HIV-positive patients with virological suppression did not have different rates of aging-relating cognitive decline compared with HIV-negative patients.
HIV-positive individuals with higher alcohol levels performed worse on several cognitive tests, however alcohol was not the primary factor.
HIV patients had reduced brain volume and poorer cognitive performance.
Patients with HIV treated with cART have lower neuropsychological test scores than controls, but no significant neuropsychological decline over time.
Evaluating the risk factors of neurocognitive decline in HIV.
Effective cognitive screening instruments are needed in order to assess and manage milder forms of HIV-associated neurocognitive disorders.
Early detection and robust treatment are critical to limiting deficits in achieving developmental milestones in HIV-infected infants.
The results indicate HERV-K activation as a potential mechanism for HIV-associated ALS.
For the most part, symptoms tend to subside after treatment initiation.
Until now, it was thought that HIV-related inflammation protected the brain from amyloid deposition.
Paroxetine use improved cognitive impairment and reduced inflammation in HIV patients.
The URMC-099 compound combined with antiretroviral therapy significantly reduced HIV levels.
CSF cultures were negative despite worsening meningitis infection.
Researchers are now testing whether antiretroviral drugs used to treat HIV/AIDS are effective in ALS patients.
The findings may have implications for the development of future vaccines.
The new treatment would need to be combined with other HIV drugs or antibodies.
The brain can harbor active HIV even after seemingly successful antiretroviral treatment.
Some coping strategies like substance abuse may have negative affects on overall health.
Neurology Advisor Articles
- Rasagiline Plus Riluzole is Safe, May Improve Survival in ALS
- Treatment of New-Onset Epilepsy: AAN, AES Update Practice Guidelines
- Gender Differences in the Epidemiology of Migraine
- Changes in Glucose Regulation in Parkinson Disease
- Apomorphine Infusions Improves Off Time Associated With Parkinson Disease
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- Locally Asymptomatic Ischemic Stroke May Present as Migraine Aura
- Associations Identified Between Stroke Severity, Recovery of Visuospatial Neglect
- Action Tremor May Have Central Origin in Motor Neuron Disease
- Characteristics Affecting Health-Related Quality of Life in RRMS, Progressive MS
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd